Bio-Techne Corporation (TECH)

Market Cap	11.36B +23.4%
Revenue (ttm)	1.22B -0.4%
Net Income	181.84M +147.8%
EPS	1.16 +152.2%
Shares Out	156.82M
PE Ratio	62.47
Forward PE	35.94
Dividend	$0.32 (0.44%)
Ex-Dividend Date	Aug 24, 2026

Volume	2,182,570
Open	72.51
Previous Close	72.45
Day's Range	72.44 - 72.52
52-Week Range	43.20 - 72.69
Beta	1.30
Analysts	Hold
Price Target	70.50 (-2.7%)
Est. Earnings	Nov 4, 2026

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,000
• Stock Exchange: Nasdaq
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In fiscal year 2026, Bio-Techne's revenue was $1.22 billion, a decrease of -0.38% compared to the previous year's $1.22 billion. Earnings were $181.84 million, an increase of 147.86%.

Analyst Summary

According to 13 analysts, the average rating for TECH stock is "Hold." The 12-month stock price target is $70.5, which is a decrease of -2.70% from the latest price.

Price Target

$70.5

(-2.70% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error